MicroRNA circuits and regulatory networks: emerging therapeutic paradigm

ABSTRACT

MicroRNAs (miRNAs) are small non-coding RNAs whose function is to regulate gene expression post-transcriptionally. Transcription factors (TFs) are the DNA-binding proteins responsible for activation or repression of a gene. Together, miRNAs and TFs form regulatory networks that modulate cellular homeostasis. In these regulatory networks, these TFs often regulate the expression of miRNAs, and in turn, miRNAs regulate the expression of TFs, thus forming feedback and feedforward loops. These loops and regulatory networks allow precise control over gene expression patterns by enabling accurate signal processing. Utilizing mathematical modelling and machine learning approaches helps understand the global structure of these networks. These reveal cellular fate selection, stress adaptation, disease development, and gaining insights into these interconnected regulatory systems opens new prospects for novel biomarker discovery and therapeutic approaches in a variety of disciplines, including cancer and immunotherapy.

GRAPHICAL ABSTRACT

1. Introduction

Cellular life requires a controlled mechanism of gene expression to maintain homeostasis and perform complex developmental processes. Since the beginning of the conceptualization of biology, the flow of genetic information was strictly through the central dogma, where RNA was considered an intermediary step between DNA and the synthesis of protein, until the discovery of the lin-4 locus from Caenorhabditis elegans by the research groups of Victor Ambros and Gary Ruvkun in 1993. The revelation of lin-4 as a non-protein-coding locus, which instead of producing a protein resulted in a small non-coding RNA. This non-coding RNA was then discovered to suppress a heterochronic nuclear protein, LIN-14, by binding to its complementary 3’-untranslated region (UTR) [1] [2]. In the year 2000, another non-coding RNA, let-7, was found to have evolutionary conservation across several species, including humans and established miRNAs as potent post-transcriptional regulators [3]. Mature miRNAs are small, single-stranded non-coding RNAs, of approximately 18–25 nucleotides. Canonical biogenesis of miRNAs starts with pri-miRNAs of ~150 nucleotides produced by transcription through RNA polymerase II, which are further processed by microprocessor complexes (Drosha and Dicer), resulting in the formation of mature miRNA duplexes [4,5]. The non-canonical pathway, on the other hand, results in the synthesis of miRtrons, where the intragenic segments are directly sliced and processed [5,6]. miRNAs function by recognizing a six-nucleotide sequence complementary to 3’UTR of an mRNA and present at the 5’ terminus of the miRNA, known as the seed region [7]. This complementarity of miRNA with mRNAs results in highly efficient regulatory prospects, wherein a single miRNA is sufficient to regulate hundreds of distinct target mRNAs, also, a single gene can be co-targeted by several miRNAs [8]. The basic titrative mechanism of miRNA activity involves its integration with proteins related to the Argonaute (AGO) family into the multi-enzyme RNA-induced silencing complex (RISC). The thermodynamic degree of complementarity determines the target transcript’s final fate, partial complementarity results in translational inhibition or accelerated deadenylation, while near-perfect sequence matching triggers endonuclease-mediated mRNA degradation [9,10]. Traditionally considered suppressive modulators, several studies have shown these miRNAs to have inducing properties under specific cellular conditions [11,12]. This diverse functional role of miRNA makes it an important component for the regulation of fundamental biological processes, including cellular differentiation, synaptic plasticity and growth of the embryo [13,14]. Because individual miRNA-target interactions are usually moderately fine-tuned and repressive, they rarely result in independent phenotypic alterations across endogenous genomic architectures. Rather, their widespread presence and evolutionary conservation result from their incorporation with TFs into larger genetic interactomes, where they support the stability and resilience of genetic regulation networks [14,15]. The primary regulators of transcriptional networks, TFs act by binding to promoter and enhancer regions to modulate gene expression. TFs and miRNAs together when regulating a downstream gene, resulting in the formation of regulatory motifs, which are the building blocks of gene regulatory networks [16,17]. Based on the directionality of these interactions, feed-forward loops (FFLs) and feedback loops (FBLs) are the two main topologies that emerge. As demonstrated by the PITX3/miR-133b regulatory circuit involved in midbrain dopaminergic neurone development and the CCND1/miR-17–20 network implicated in breast cancer progression, FBLs are generated when a TF controls the transcription of a miRNA while the mature miRNA post-transcriptionally represses that same TF [18,19]. On the other hand, FFLs are created when a TF simultaneously controls a miRNA that targets the same gene and a protein-coding gene, producing coherent or incoherent regulatory reactions. One of the most well-studied instances of this design is the TP53-centred miRNA regulatory network [17,20]. By enhancing robustness, filtering biological noise, shaping temporal responses, and maintaining gene-expression homeostasis, these regulatory motifs perform essential systems-level functions [15,21]. Target transcripts actively compete for a small intracellular pool of miRNAs beyond these direct regulatory loops. Long non-coding RNAs, circular RNAs, pseudogenes, and messenger RNAs fight for shared miRNAs through common miRNA response elements (MREs), consequently indirectly impacting each other’s expression. This mechanism, which is known as the competing endogenous RNA (ceRNA) hypothesis, results in a further layer of post-transcriptional RNA regulation [22,23]. Many clinical disorders are caused by disruption of these complex regulatory networks. Through aberrant gene regulation, abnormal miRNA expression has been linked to metabolic problems, viral infections, cardiovascular illnesses, and several forms of cancer [14,24]. For example, dysregulation of the miR-21 and miR-183 families has been associated with tumour progression and plays a role in metastasis in several malignancies, whereas miR-34a is considered a tumour suppressor and a potent regulator of immune responses within the tumour microenvironment (TME) [24,25]. Due to its ability to accurately reflect physiological and pathological cellular states, miRNA expression signatures have emerged as important diagnostic, prognostic, and therapeutic biomarkers across various diseases [26,27]. With the help of synthetic biology to predict base pairing, modularity and lower metabolic burden of RNA molecules, it has become easier to devise programmable genetic circuits. RNA-based regulators, such as riboswitches, RNA aptamers, small interfering RNAs, and artificial miRNAs (amiRNAs), provide better flexibility, quick response times, and easier computational design than traditional protein-based transcription factors, which frequently show complicated folding parameters, slower response kinetics, and possible off-target effects [28,29]. Researchers have developed miRNA-responsive sensor circuits that can identify endogenous miRNA expression profiles and apply Boolean logic operations for cell-state classification by introducing particular miRNA target sites (miRTs) into the 3’ untranslated region (3’-UTR) of synthetic constructs [30,31]. In the presence of disease-associated miRNAs, these sensors relied directly on RISC-mediated regulation of reporter genes. Despite their effectiveness, these systems usually showed basal leakage, restricted dynamic range, and decreased sensitivity in identifying minute variations in miRNA abundance, which resulted in the development of more complex multilayered RNA regulatory circuits [29,30].

To overcome these constraints, the subsequent generation of synthetic gene circuits uses intricate multigene architectures integrated onto single plasmid vectors. Logical building of multi-cassette regulatory circuits on a single genetic backbone is done by using molecular design software like SnapGene and computational modelling platforms like TinkerCell to simulate dynamic networks [32,33]. By incorporating these synthetic genetic parts into feed-forward and feedback regulatory networks. Modern gene circuits mimic biological buffering processes, minimize stochastic gene-expression noise, and produce extremely sensitive switch-like responses to enable precise cell-state categorization [30,31,34]. Thus, synthetic biology has emerged from single RNA-mediated silencing of a gene towards sophisticated multilayered regulatory networks for autonomous disease sensing and highly specific and personalized therapeutic applications.

Gene regulation has undergone a fundamental evolution, moving beyond the classical one gene-one protein hypothesis towards highly interconnected regulatory networks, which are characterized by a systems-level approach [35,36]. Transcription factors (TFs) and miRNAs are two complementary stages of gene regulation in this system, responsible for modulating the expression of each other [9,10]. This multifaceted regulation helps achieve highly specific temporal and spatial control over the target [15,17]. These regulatory networks play an important role in biological functioning, and dysregulation of these circuits results in various disease progressions such as cardiovascular diseases, neurodegenerative diseases, metabolic syndromes and cancer [24,37]. This programmable nature of TF-miRNA interactions has provided ways to make cellular switches through the development of synthetic gene circuits [30,31]. This review emphasizes on the regulatory role of TFs and miRNAs, crosstalk between the regulatory networks and how it can be exploited for therapeutic interventions.

2. miRNA biogenesis and its functional role in regulating gene expression

2.1. Canonical and non-canonical biogenesis pathways

Apart from the traditional canonical pathway, miRNA biogenesis includes several non-canonical routes that diversify miRNA production and function [38]. The canonical pathway begins with the transcription of miRNA genes by RNA polymerase II, producing a long primary miRNA transcript (pri-miRNA). This pri-miRNA is a stem-loop structure that consists of 32 nucleotide stem base pairs and a terminal loop. These are modified to include 5’-capping, splicing and polyadenylation at the 3’ terminus, and also consist of several hairpin loops for production of distinct mature miRNAs. Within the nucleus, the first processing is done by the microprocessor complex Drosha and DGCR8. Drosha is an RNase III enzyme, and DGCR8 is an RNA-binding protein which guides Drosha to cleave at specific bases to generate precursor miRNA (Pre-miRNA) [38](Yang & Lai, 2011). Exportin-5 for the transport of the pre-miRNA to the cytoplasm in a Ran-GTP-dependent manner. In the cytoplasm, a second level of processing is performed by the RNase III enzyme, Dicer, which cleaves the pre-miRNA to produce a ~ 22 nucleotide miRNA duplex. This duplex consists of a guide strand and a passenger strand. The passenger strand usually gets degraded, and the guide strand, which becomes the mature miRNA with its base pairing ability with Argonaute (Ago) protein, is responsible for the formation of the RNA-induced silencing complex (RISC) [39]. This RISC complex is responsible for suppression and activation of target genes Figure 1(A).

Figure 1.

Canonical and non-canonical pathways of miRNA biogenesis.(A) canonical miRNA biogenesis begins with RNA polymerase II-mediated transcription of primary miRNA (pri-miRNA), followed by nuclear processing by the DROSHA-DGCR8 microprocessor complex to generate precursor miRNA (pre-miRNA). (B-H) Representative non-canonical miRNA biogenesis pathways bypass either DICER or DROSHA processing. (B) DICER-independent maturation of miR-451 through direct AGO2-mediated cleavage. (C) Mirtron pathway, in which spliced introns fold into pre-miRNA-like hairpins following debranching. (D) small nucleolar RNA (snoRNA)-derived miRNA pathway. (E) transfer RNA (tRNA)-derived miRNA pathway. (F) tRnase Z-dependent pathway, where tRNA-like precursors are processed into miRnas. (G) small hairpin RNA (shRNA)-derived miRNA pathway. (H) viral tRnase Z-dependent pathway. Collectively, these pathways highlight the diversity of miRNA biogenesis mechanisms that converge on functional mature miRnas capable of regulating gene expression.

There are several non-canonical pathways for biogenesis of miRNAs which bypass key steps of the canonical pathway, which involves processing with Drosha and DGCR8 and Dicer [38]. For example, the generation of mirtrons, which are short introns that fold into pre-miRNA-like hairpin structures followed by splicing and debranching, skipping Drosha cleavage [40]. Further, they converge on the canonical pathway at the nuclear translocation step of exportin-5-mediated translocation Figure 1(C). Small nucleolar RNAs (snoRNAs) are another source of miRNAs, which are processed and generate functional, snoRNA-derived fragments (sdRNAs) having miRNA-like features Figure 1(D) [41]. Along with these, several other endogenous short hairpin RNAs (endo-shRNAs) and certain tRNA precursors produce miRNA-like small RNAs through a Dicer-dependent but Drosha-independent biogenesis pathway Figure 1(E, G) (Yang & Lai, 2011) [38]. An alternative miRNA maturation mechanism involving a Drosha-dependent but Dicer-independent pathway is demonstrated by miR-451 biogenesis (Figure 1(B). Here, Drosha cleaves pri-miR-451 and produces an exceptionally short pre-miRNA typically around 41–42 nucleotides. Because of its shorter length, it could not be recognized by Dicer and gets directly loaded onto AGO, which then gets spliced to produce mature miR-451 [39]. Additionally, tRNA-derived small RNAs (tsRNAs) are suggested to have a role in miRNA biogenesis. These are generated by RNase Z cleavage of pre-tRNAs and transcription termination by RNA polymerase III, forming a class of small RNAs other than classical miRNAs. Some tsRNAs are both Dicer-dependent and independent, but all of them are tRNase Z-dependent Figure 1(F, H). These tRNA-derived fragments may compete with pre-miRNAs for Dicer and with miRNAs for AGO proteins, affecting miRNA biogenesis [42]. Concurrently, both the canonical and non-canonical pathways demonstrate the complex and versatile methods of miRNA biogenesis, which is essential for regulation of downstream signalling genes.

2.2. Evolutionary sequence conservation of non-coding RNAs and miRnas

Based on their class and function, non-coding RNAs (ncRNAs) exhibit different levels and patterns of evolutionary conservation. Although ncRNAs are typically less conserved than protein-coding genes, even in instances where the entire sequence varies, functionally significant portions can be preserved through evolution. In a mature miRNA, the 5’ region is the most conserved, and conservation is particularly significant. This region contains the seed sequence (nucleotides 2–7), important to recognize complimentary sequences in target mRNAs. Base pairing through the 3’-region contributes to specificity and regulatory strength, this particular 3’-end can tolerate more variation in nucleotide sequences. The seed region, necessary for target recognition and thus its conservation is essential and even a minute variation in nucleotide sequence alters the set of transcripts regulation by a miRNA [43].

Target sites of conserved miRNAs also exhibit conservation, specifically sequences that are complementary to the miRNA seed in the target mRNAs’ 3’ untranslated regions (3’ UTRs). The preferential maintenance of conserved 7–8 nucleotide seed-matched locations across related species suggests miRNA–target interactions may be subject to evolutionary selection. Therefore, in the design of a miRNA-based synthetic regulatory circuit, conservation can be applied at two complementary levels first, conservation of the corresponding target-binding sequence shows that this interaction is biologically operational and second, conservation of the miRNA 5’ seed region supports the selection of a stable and efficiently characterized regulatory data input. Therefore, conserved seed-matched target sites can be an appropriate position to start creating miRNA-responsive components for synthetic circuits. However, as conserved connections do not always ensure comparable regulatory efficacy in a synthetic environment, conservation should be paired with miRNA expression, target accessibility, tissue specificity, and experimental evaluations of suppression [44].

3. Architecture and functional principles of endogenous and synthetic miRNA regulatory networks

3.1. Endogenous miRNA regulatory networks

Endogenous miRNAs form a crucial layer of post-transcriptional gene regulation rather than controlling individual genes on their own, function as a component of interconnected gene regulatory networks. The miRNA genes are translated from the genome to generate primary miRNA (pri-miRNA) transcripts, which are then converted into precursor miRNAs and mature miRNAs. Mature miRNAs bind to the RNA-induced silencing complex (RISC) and guide complex through base pairing between the miRNA seed region and corresponding sequences in the 3’ UTR of target mRNAs [45]. Translational repression and/or mRNA destabilisation are usually the outcomes of this interaction, which reduces the quantity of protein produced through the target gene. Endogenous miRNAs generate highly linked regulatory networks since individual mRNAs can be targeted by several miRNAs and a single miRNA can regulate many target mRNAs. The underlying operational principles used in designed genetic circuits are very different from the architectural logic driving native non-coding RNA networks [10]. The primary role of endogenous miRNA networks is analogical regulation. miRNAs are incorporated into intricate co-regulatory motifs in conventional cellular contexts, such as feed-forward loops (FFLs) driven by master transcription factors (TFs) and auto-regulatory feedback loops. In these natural cascades, a single TF frequently induces the production of precursor miRNA (pre-miRNA) and triggers the transcription of a target messenger RNA (mRNA). The mature miRNA attaches to complementary sequences in the 3’-untranslated region (3’−UTR) of target transcripts after being cytoplasmically processed by Dicer and loaded into the Argonaute 2 (AGO2)-containing RNA-induced silencing complex (RISC) [46].

This natural configuration serves as a signal buffer and noise filter, fine-tuning gene expression within specific physiological thresholds instead of enforcing binary ON/OFF control (Figure 3). Moreover, endogenous miRNAs have a high degree of pleiotropy; an individual miRNA sequence usually controls hundreds of different mRNA targets in order to maintain homoeostatic balance along a wide range of cellular pathways [46,47].

Figure 3.

Comparative biological architecture of endogenous and synthetic miRNA regulatory circuits. endogenous miRNA networks: native non-coding networks operate as analog regulatory devices. A master transcription factor (TF) concurrently activates target mRNA expression and precursor miRNA transcription, establishing a co-regulatory feed-forward loop (FFL) that buffers transcriptional noise and maintains physiological homeostasis across broad target networks via processing by Dicer and loading into the RISC/AGO2 complex. Synthetic miRNA logic circuits: engineered biological circuits function as high-contrast cell-state classifiers. Intracellular miRNA profiles (e.g. high expression of oncogenic miR-21 combined with low expression of tissue-specific miR-122) serve as operational inputs that engage synthetic miRNA response elements (MREs) within an engineered Boolean logic unit. Relief of translational repression conditionally drives targeted expression of a therapeutic payload with high cell-type orthogonality.

3.2. Synthetic miRNA regulatory networks

By incorporating artificial, programmable regulatory networks into target cells, synthetic biology builds upon this natural machinery to enable us to take control of and reprogram these endogenous metabolic pathways. Similar to a conventional electronic circuit, a synthetic circuit is an artificial network of genetic elements designed to function inside a living cell. It can sense biological inputs, analyse information, and produce consistent, physiologically active outputs. A constitutive promoter (pCMV), operator (Opt), inducible repressor, miRNA expression cassette, and reporter gene make the synthetic gene circuit. The repressor turns inactive when the inducer is present, allowing the reporter and miRNA to be transcribed. When the inducer is not present, the active repressor binds the operator and stops transcription, which stops the synthesis of miRNA (Figure 2). These circuits enable researchers to rewire genomic processes under tightly controlled conditions rather than relying on the cell’s predefined programming. This approach is referred to as cybergenetics, which combines biological engineering, control theory, and mathematical modelling to dynamically modify gene expression [48]. These circuits offer a potent experimental setting to assess the predictability inherent in biological networks and have enormous therapeutic potential, such as creating sophisticated logic gates that can recognize and eliminate cancer cells with precision [30]. Modular genetic parts arranged into functional modules make up a typical synthetic circuit. These components usually include promoters, protein-coding sequences (CDS), and specific regulatory DNA elements. These modules can be roughly classified as regulators and targets within modern repression of transcription circuits. The target module consists of the gene of interest or a fluorescent reporter of the gene, while the regulator module encodes a synthetic repressor protein, such as the Tetracycline Repressor (TetR), which physically binds to target DNA through its highly specific helix-turn-helix DNA-binding domain to prevent initiation of transcription actively. Importantly, the target’s promoter region is designed to have certain processing-anchored structures, including artificial Tet operator sites (tetO), which enable the regulator elements to assemble, regulate, or sterically prevent RNA polymerase from executing exact ON/OFF states [49].

Figure 2.

Design and mechanism of an inducible synthetic miRNA gene circuit. the schematic illustrates an engineered plasmid containing a constitutive CMV promoter (pCMV), operator (opt), inducible repressor, miRNA cassette, reporter gene, and transcription terminator (Ter). Following transfection into cells, the circuit functions in two states. In the presence of the inducer, the repressor is inactivated, permitting transcription of the miRNA and reporter gene (ON state). In the absence of the inducer, the active repressor binds the operator, repressing transcription and preventing miRNA expression (OFF state). This synthetic circuit enables inducible and reversible control of miRNA expression.

To ensure that each transfected cell gets the complete, optimal stoichiometric framework of the network and to mitigate the unforeseen consequences of transfection resource competition, the entire multi-cassette synthetic circuit is methodically constructed onto a single plasmid vector instead of multiple distinct plasmids. The designing process starts in silico by simulating the network’s interaction kinetics and dynamical differential equations using computational modelling software packages like TinkerCell [50]. Further after the optimization, to prevent transcriptional read-through, repressors, promoters, and loop arrays are arranged into distinct cassettes separated by strong polyadenylation (pA) signals using molecular biology software suites such as SnapGene and are used to physically map and simulate the assembly of the DNA fragments. The fully developed physical plasmid construct is subsequently introduced into the host cell using viral vectors or conventional transient transfection, where it expresses the designed circuit using the cell’s natural transcription and translation machinery [51]. These circuit’s architectural design adds extremely complicated regulatory networks, enabling synthetic biologists to develop complex, autonomous structures that go beyond conventional open-loop systems. Researchers may establish incoherent feed-forward loops (iFFLs), in which an activator activates simultaneously a target gene and a miRNA that suppresses the same target gene, or negative feedback loops (FLs) that restrict accumulation of transactivator by altering the location of miRNA target sites [34]. These sophisticated motifs can even function as automatic OFF-switches when combined with ligand-responsive ribozymes or nested into hybrid loops (HYBs) [52]. Ensuring cellular homeostasis, reducing expression noise, providing strong dynamic adaptation, successfully limiting vector toxicity, and maximizing protein production by removing expression burden onto the cellular environment all depend on this high-level architectural complexity.

Synthetic miRNA circuits, on the other hand, are made to function as high-contrast digital switches intended for accurate cell-state classification (Figure 3). Synthetic circuits use intracellular miRNA concentrations as sensory signals to carry out pre-programmed Boolean logic operations (such as AND, NOT, and OR gates) instead of fine-tuning endogenous pathways [30]. A synthetic cell-classifier circuit, for instance, can assess a particular molecular signature, such as the combination of low expression of a tissue-specific marker (like miR-122) and high expression of an oncogenic marker (like miR-21). Synthetic miRNA Response Elements (MREs) included in a promoter-reporter or therapeutic gene cassette are activated by these miRNA inputs. Post-transcriptional repression at the MRE cassette is released when the specified biomarker condition is satisfied, conditionally initiating the high-level production of a therapeutic payload [53,54].

3.3. Network topology

A multifaceted paradigm of intracellular regulation is represented by the structural framework of miRNA regulatory networks. These short non-coding RNAs are incorporated in complex genomic structures that integrate transcriptional and post-transcriptional mechanisms to precisely regulate the cellular phenotype, instead of operating as discrete, unidirectional pathways [55,56]. TFs and miRNAs interact in heterogeneous regulatory networks formed by thousands of distinct genetic connections [17]. A potent dual-level control mechanism over shared target genes is established by this structural assembly [57]. The miRNA-TF co-regulation frequently arranges itself into recurrent circuit patterns called feedback loops (FBLs) and feed-forward loops (FFLs) [17]. A vital biological buffering mechanism is provided by this dual-layered standard regulatory framework [57,58]. Their potential to act combinatorially, which enables a particular miRNA to titrate hundreds of different transcribed genes while allowing multiple miRNAs to interact with a specific target, is their evolutionary competitive advantage because distinct miRNA-target interactions typically result in relatively weak regulatory action [59]. As a homeostatic filter, this dense, titrative cross-talk protects the cell from noise resulting in stochastic gene expression, stops leaky transcript expression from varying promoters, and sets precise activation thresholds that stabilize cellular phenotypes [57,58]. Finally, by structurally mapping across various biophysical modalities, this multi-layered integration, including transcriptional initiation, chromatin modifications, post-transcriptional processing, and post-translational modification, enables the coordination of cellular sensing, downstream decision-making, and phenotypic actuation [55,56]. The synthetic gene circuit consists of integrate framework, including sensor, processor and actuation units Figure 4(A). The processed signal is converted into actuation, leading to controlled expression of an output protein, such as GFP. Gene regulation can be implemented at multiple levels, including transcriptional, post-transcriptional, and post-translational control, providing precise regulation of gene expression Figure 4(B-D). The development and optimization of these circuits follow the iterative Design-Build-Test-Learn (DBTL) cycle, which enables systematic refinement of circuit performance and functionality Figure 4(E).

Figure 4.

Integrated platform for synthetic gene circuit engineering. (A) overview of the synthetic gene circuit workflow, comprising sensing of extracellular or intracellular signals, genetic information processing, and actuation through regulated protein expression. (B-D) gene regulation at different levels, including (B) transcriptional, (C) post-transcriptional, and (D) post-translational control. (E) the design-build-test-learn (DBTL) cycle for iterative optimization of synthetic gene circuits.

4. Core network motifs

These hybrid networks, seen in both evolutionary biology and synthetic architecture, are constructed from recurrent structural patterns known as network motifs. These small-scale circuits process complicated information to perform specialized cellular functions, as shown by their diverse topological structures [21]

4.1. Feedforward loops

The feed-forward loop is recognized as one of the most common three-node network patterns in gene regulation systems Figure 5(B). This motif, which was initially found in Escherichia coli’s transcriptional system and later discovered across numerous eukaryotic organisms, is composed of a master regulator which operates on a terminal gene target via two independent concurrent pathways [60]. The direct channel features the master regulator directly influencing the target, whereas the indirect approach involves the master regulator regulating an intermediate molecule, which in turn influences the same terminal target [21]. There is a significant abundance of feed-forward loops within mammalian genomes, in which miRNAs operate as posttranscriptional regulatory elements of the network [17]. These miRNA-driven circuits are critical endogenous regulators of cellular processing, proliferation, differentiation, DNA synthesis, and cell cycle progression in both healthy and malignant conditions [61]. Feed-forward loops can be characterized as coherent or incoherent based on the regulatory indicators of their interactions. The overall sign of the loop is calculated by multiplying the signs of its component routes, with activation representing a positive sign and repression indicating a negative sign. This mathematical categorization corresponds precisely to the specific biological functions that the loop was evolutionarily built to handle. While coherent loops excel at creating spatial boundaries and leading to all-or-none transitions, incoherent loops specialize in temporal planning, noise buffering, and maintaining developmental resistance to environmental or intrinsic perturbations. [21,58]

Figure 5.

Structural topologies of miRNA-Mediated network motifs and the FOXO1/miR-486-5p regulatory axis. this schematic outlines the fundamental architectural network motifs governing miRNA regulation alongside a specific biological application. (A) and (B) define basic feedback (FL) and feed-forward loops (FFL) between transcription factors (TF), miRnas, and downstream targets. (D) and (E) differentiate between coherent FFLs (cFfls) and incoherent FFLs (iFfls) where parallel pathways exert either synergistic or opposing regulatory signs on a target, while panel (F) displays an intronic miRNA self loop (iMSL) regulating its host gene. Structurally embedding these motifs, panel (C) illustrates a context-specific mutual inhibition positive feedback loop (PFL) where an external stimulus, such as doxycycline, drives a bistable switch between the transcription factor FOXO1 and miR-486-5p.

4.1.1. Coherent feed-forward loops (cFFLs)

Coherent feed-forward loops are defined as regulatory pathways that generate the identical overall sign of target regulation via direct as well as indirect arms [21]. The most common instance of such a loop is when a master transcription factor activates a target gene while also inhibiting a miRNA that targets the same gene Figure 5(D). Because the indirect approach efficiently alleviates miRNA-dependent repression of the target, both arms operate together to enhance target expression. The physiological implication of this coherent design is the imposition of mutually exclusive spatial expression [61]. Because miRNAs and target genes can’t readily reside in the same cellular conditions, these loops operate as robust spatial fail-safe mechanisms, confining specific molecules to target regions or tissues during multicellular development. In therapeutic contexts, like the study of human epithelial tumours, coherent loops are critical for establishing cellular integrity and preventing phenotypic overlap. In type 1 epithelial tumour cells, a pair of interrelated coherent feed-forward loops comprising the miRNA miR-199a, the transcriptional component Brm, and the TF EGR1 impose the all-or-none expression of tumour-specific genes [62]. Similar to this, during human adipogenesis, miR-27a/b-3p regulates a restrictive ratio between the positive adipogenesis regulator PPARG and its endogenous inhibitor SCAMP3. The loop regulates adipose tissue cell proliferation by precisely regulating the opposing target proteins [63]. Coherent loops not only regulate growth but also stabilize key transition sites in the cell cycle. The shift between the G0/G1 and S phases is heavily dependent on the regulated stoichiometric ratio of E2F1 and its binder RB1, which is structurally protected from molecular disturbances by a coherent feed-forward loop mediated by the miR-17 family [64]. During inflammatory oncogenic signalling, the transcription factor NF-κB, cytokine IL-6, and miRNA let-7 form a molecular AND logic gate. To reach the IL-6 activity level required for cellular transformation, both regulatory routes must be activated, effectively protecting the system against accidental inflammatory triggering produced by brief upstream noise generation [65].

4.1.2. Incoherent feed-forward loops (iFfls)

Compared to their coherent equivalents, incoherent feed-forward loops have regulated routes with contrasting signs [21]. A frequent form of this motif includes a master transcription factor responsible for the activation of both a target gene and a miRNA which suppresses the same target [17] Figure 5(E). Instead of inhibiting co-expression, this competing design is intended to cause a temporal phase shift. Because the suppression of miRNA transcription, processing, and translation-level take longer than direct transcription of the target gene, the direct arm of the loop causes rapid, early accumulation of the target protein. When the slower miRNA-mediated arm joins up, it represses the target gene, resulting in a unique, brief temporal spike of protein expression [21]. Apart from temporal scheduling, incoherent feed-forward loops serve as excellent biological noise filters. Researchers have shown that such circuits are ideally equipped to shield distal targets from transcriptional variations using mathematical modelling and stochastic simulations. When upstream signals get upregulated suddenly, both the target and its repressing miRNA are stimulated at the same time, allowing enhanced miRNA function to prevent the target spike [58]. In the cell cycle, this noise-buffering property is very important, where the proto-oncogene c-MYC results in direct activation of the TF E2F1 while also activating the miR-17–92 cluster to suppress E2F1 translation, leading to a stable baseline for cell-cycle progression [66]. This protective behaviour is found in tissue pruning during development, when miR-263a uses an incoherent loop to buffer the pro-apoptotic gene hid, to prevent accidental cell death in developing sensory organs [67].

The self-correcting design of incoherent loops enables them to adapt to fleeting environmental cues and identify fold-changes. These loops allow cells to react to relative changes in signal parameters rather than absolute values, and ensure consistent cellular reactions across varied tissue conditions [68]. Furthermore, under some situations, incoherent loops can cause or stabilize biological oscillations. The rhythmic behaviour of the miRNA lin-4 synchronizes the timing of the stages of development in Caenorhabditis elegans embryos. Through an incoherent feed-forward loop that targets the transcription factor lin-14 post-transcriptionally, lin-4 transforms the pulsatile dynamics of lin-14 into a dependable temporal gradient that serves as a developmental clock [69].

4.1.3. Intronic miRNA-Mediated self-Loops (iMsls)

Intronic miRNA-mediated self-loops are a highly specialized and structurally compact variant of the incoherent feed-forward loop Figure 5(F). In this particular genomic architecture, a miRNA is contained within the intron of a host gene, implying that both the host protein and the miRNA are being produced from a single genomic locus by a common upstream TF. After slicing and processing, the intronic miRNA binds directly to the messenger RNA of its host gene, resulting in an immediate post-transcriptional negative feedback loop [70]. According to recent studies, these self-loops are considerably enriched in mammalian genomes, accounting for around 20% of all intronic miRNAs expected to target host genes [71]. The removal of transcriptional delays is the biological advantage of combining an incoherent feed-forward loop into a single genetic location. The target gene and the miRNA are transcribed from separate loci in a classic incoherent loop, which causes a delay as both loci become active. However, in an intronic self-loop, the regulatory miRNA and the host mRNA are produced simultaneously [70]. This temporal synchronization enables precise gene dosage adjustment, remarkable noise reduction, and quick, real-time gene expression adaption. These self-loops give cells an effective, localized way to self-limit protein levels and preserve strict homeostatic equilibrium by explicitly linking the regulator’s production to the target [34]

4.2. Feedback loops

One of the most prevalent patterns in miRNA-mediated gene regulatory networks is feedback loops. These circular topologies permit downstream network outputs to directly affect upstream input’s activity levels Figure 5(A). Based on the loop’s overall qualitative impact, feedback mechanisms in biological systems are categorized as either positive or negative. Positive and negative feedback loops function as essential molecular control units when combined with post-transcriptional regulators such as miRNAs. They regulate everything from cellular switchboards and memory-like persistence to noise buffering and temporal oscillations, guaranteeing the developmental robustness and high precision of genetic networks.

4.2.1. Positive feedback loops and signal persistence

Positive feedback loops are designed to undergo self-amplification, converting short-lived upstream inputs into steady, long-lasting cellular reactions. In these circuits, an initial stimulus activates a chemical cascade in which the output either suppresses its own inhibitors or further stimulates its own production. This technique, which enables a cell to stably lock into a certain differentiated state or inflammatory phenotype even after the initial signal has faded, is essential for cell-fate specification and epigenetic memory in mammalian cells. Human breast cells exhibit a classic, well-documented example of this persistent behaviour during an inflammatory reaction. Here, a complicated network including the transcription factor NF-κB, the RNA-binding protein LIN28, and the miRNA let-7 forms a positive feedback loop. NF-κB, a master regulator of inflammation, is activated by the tyrosine kinase Src, starting the cascade. After that, NF-κB transcriptionally promotes LIN28, a protein that directly prevents let-7 from being processed and matured. Let-7 is a naturally occurring post-transcriptional inhibitor of the cytokine interleukin-6 (IL-6); therefore, when LIN28 suppresses it, IL-6 expression significantly increases. Afterwards, IL-6 activates NF-κB to complete the circular network. Despite the complete lack of the initial Src-triggering input, this self-sustaining cellular loop keeps cells in an active, inflammatory state [65].

This loop may act as a double-negative feedback loop, which is a structural variant of positive feedback in which two elements suppress each other. Environmental stresses such as chemotherapeutic medicines and clinical radiation can significantly alter the let-7/LIN28 toggle switch in non-small cell lung cancer. This system permanently shifts into a high-LIN28 state when these stressors cause let-7 to be downregulated, which promotes oncogenesis and leads to clinical chemo- and radio-resistance in the tumour tissue [65]. The transcription factor AP-1, the tumour suppressor Pdcd4, and miR-155 are involved in a comparable positive feedback loop. This positive loop, responsible for promoting the development of tongue cancer, is driven by overexpression of miR-155; however, miRNA knockdowns can effectively break the loop, causing the cells to undergo apoptosis and tumour regression [72](Zargar et al., 2019).

4.2.2. Negative feedback loops and homeostatic control

As compared to positive loops, which are self-amplifying in nature, negative feedback loops are self-limiting. A TF triggers the production of a miRNA gene in a typical miRNA-mediated negative feedback loop. This miRNA, upon binding to the transcription factor’s messenger RNA, results in its repression. Maintaining cellular stability, suppressing gene expression, and keeping protein levels within regulated physiological control all depend on this homeostatic configuration. The primary function of these is one of these negative feedback loops is to buffer biological noise. Translation as well as transcription rates vary as a result of both internal (intrinsic noise) and external (extrinsic noise) environmental changes in the noisy biochemical state of a cell. A negative feedback loop functions as a sophisticated absorber; in case of a transcription factor spike, it generates additional miRNA, which swiftly targets and breaks down the transcription factor’s mRNA, maintaining the protein concentration. External signalling thresholds dictate dampening expression noise in this type of loop, giving the cell cycle network the physical robustness required to avoid aberrant cell division. This buffering capability is clearly seen in the regulation of the miR-17–92 cluster [19]. Although E2F activates the transcription of the miR-17–92 cluster, individual miRNAs within this cluster suppress E2F post-transcriptionally [19,66].

4.2.3. Double-negative loops

The double-negative feedback loop (DNFL), often known as a genetic toggle switch, is a fundamental network motif that coordinates binary biological decisions [73]. A DNFL is composed of two molecular species that mutually suppress one another, typically a transcription factor and a post-transcriptional regulator, such as a miRNA Figure 5(C). The overall mathematical result of this reciprocal inhibition is a positive reinforcing loop, as each component works to inhibit its counterpart. This inability of the system’s regulatory network to steadily rest in the middle is made possible by this structure. In this, there are two mutually exclusive steady states: a state where the first component is highly active and the second is silenced, or a state where the second component dominates and the first is silenced. The network illustrates a traditional double-negative feedback loop that is structurally arranged as a mutual inhibition motif between the miRNA miR-486-5p and the transcription factor FOXO1. In this design, FOXO1 is first activated by an upstream inducer molecule, such as doxycycline, and then represses the expression of miR-486-5p. In turn, FOXO1 is inhibited by miR-486-5p. The system operates theoretically as an overall positive feedback loop (PFL) because both of these negative regulatory linkages cancel one another out in a closed loop. This arrangement creates a biological toggle switch with two mutually exclusive states: high levels of miR-486-5p keep FOXO1 in an OFF state in the absence of a strong stimulus, while highly expressed FOXO1 inhibits its own repressor to maintain its ON state Figure. The major cause of tumour growth, tissue invasion, and treatment resistance in cancer is the aberrant regulation of double-negative feedback loops (DNFLs). The Epithelial-to-Mesenchymal Transition (EMT) and its opposite process, the Mesenchymal-to-Epithelial Transition (MET), control the transition between states during the metastatic pathway [74]. The miR-34/SNAIL loop and the miR-200/ZEB loop are two interrelated mutual inhibition circuits that make up the basic components responsible for these phenotypic changes [75]. To preserve a stable, non-migratory epithelial phenotype, baseline activation of miRNAs suppresses their transcription factor equivalents under physiological settings [75,76]. However, this network can also settle into a tristable regime where the three stable states can occur simultaneously, which defines a hybrid, partial-EMT state where tumour cells can migrate collectively as multicellular clusters due to medium levels of ZEB and miR-200, according to mathematical modelling and empirical observations [77,78]. Lastly, the identification of parallel regulatory relationships, such as the miR-1199-5p/ZEB1 loop, shows how structurally similar but functionally different DNFLs collaborate to control the plasticity of tumour cells [79,80]. Despite providing useful conceptual frameworks for understanding and engineering regulatory dynamics, feed-forward and feedback loop behaviour in living systems is considerably more complex than that predicted by idealized circuit models. Regulatory strength, reaction kinetics, molecular degradation, cellular context, and stochastic fluctuations in gene expression decide the functional outcome of a given motif [81]. Depending on the host cell and environmental conditions, the same network topology may produce different phenotypes. Network inference and ML models can identify statistical associations or sequence-level patterns that require experimental confirmation [82]. Therefore, experimentally validated regulatory interactions and circuit behaviours should be clearly distinguished from computational predictions, particularly when these motifs are proposed for therapeutic applications.

5. Design of synthetic circuits for programmable gene regulation

5.1. Repressors and inducers

Repressors and inducers, the fundamental biophysical switches that govern cellular transcription, are at the physical core of programmable gene regulatory circuits. A repressor is a specialized DNA-binding protein that binds to a particular operator site in a promoter to actively prevent RNA polymerase from undergoing transcription of a downstream target gene. The mechanism uses inducers, which are small-molecule chemical signals, to make this transition dynamic and sensitive. Simultaneous binding of inducers to their target repressors results in a change in conformation that modifies the protein’s affinity for DNA. Such an interaction can stabilize the repressor on the promoter to switch a gene OFF or remove a bound repressor from the operator to turn a gene ON (as observed in IPTG-induced LacI systems). These repressor-inducer combinations serve as a synthetic circuit’s basic biochemical interfaces. These compounds serve as the main inputs and control points within any genetic design that may be programmed. To adjust a genetic switch’s optimum threshold, sensitivity, and dynamic range by choosing repressors with different binding preferences and cooperativity kinetics [83]. However, these switches must be extremely orthogonal that is, they must not interfere with the host organism’s natural transcription pathways or cross-react with other signalling components to be effective in complex systems [84]. This demand for clean, predictable interactions necessitates the collection, characterization, and standardization of a diverse library of regulatory proteins.

5.2. iGEM registry of standard biological parts

The International Genetically Engineered Machine (iGEM) Registry of Standard Biological Parts is the primary open-access archive for these standardized genetic elements, often known as BioBricks [85]. The registry contains thousands of modular DNA sequences that have been physically organized for easy assembly, including promoters, operators, ribosome-binding sites, protein-coding sequences, and terminators. It uses standardized physical building pieces to expand the design of programmable gene circuits beyond basic, isolated switches. The registry serves a crucial role in linking fundamental biochemistry with high-level circuit design by converting characterized repressor-inducer pairs into plug-and-play programmable modules [86]. For instance, a designer can search the registry for pre-defined components, such as a standardized promoter with a LacI operator, an optimized ribosome binding site, a purified LacI coding sequence, and a particular transcriptional terminator, instead of searching for the wild-type lac operon sequence. To accurately predict the behaviour of a particular repressor under the effect of its matching inducer is possible because these individual components are adequately documented with standardized performance metadata [86]. Genetic engineering is now an organized, predictable field rather than an ad hoc experimental process attributed to this standardization [85].

5.3. miRNA-Responsive logic gates

Biological logic gates are built by wiring conventional repressor and inducer modules consecutively from the registry [87]. Biological logic gates are designed to process one or more chemical inputs to generate one deterministic output, much like their silicon equivalents in computational engineering. Living cells can be trained to carry out intricate computational decisions, such as analysing environmental, pathogenic, or pharmacological stimuli to initiate a particular therapeutic or physiological response, by connecting transcriptional repressors in series or parallel [87]

The practical application of such logic gates is totally dependent on the correct mechanical wiring of repressor-inducer complexes [88]. For example, a simple NOT gate, the inverter, is built by stimulating the production of repressor proteins with an operational promoter; when the input (the repressor) is missing, the output gene is transcribed, but when the input increases, the repressor turns off the output promoter. To create an AND gate, which requires two independent inputs to produce an output, designers can connect two distinct repressor-binding operators upstream of the gene to be targeted. Only if both comparable chemical inducers exist to turn off the corresponding repressors can RNA polymerase properly transcribe the resulting downstream output [89]. Using well-characterized, orthogonal parts retrieved from the iGEM registry, these basic logic gates can be built and stacked into more complicated computational network structures, such as NAND, NOR, and XOR gates [90]. Cells can be programmed to act as cognitive, self-sufficient sensors suited to carry out complex decision-making processes using this structured integration, scaling from biochemical inducers to standardized BioBricks and finally to computational logic circuits [91].

The elegance of biological logic gates is found in their varying physical architectures, where different combinations of promoters, operators, and repressors alter the fundamental mathematical functions of the cell [92]. The most basic type of biological logic gate that exists is the NOT gate, also known as an inverter, which mechanically transforms a high input signal to a low output signal through the placement of a target reporter gene beneath the control of a constitutively active promoter. Upon introducing an input repressor protein, it results in binding at the promoter’s operator site, leading to suppressed transcription, thus turning the output OFF. To invert this signal, a buffer gate is introduced, which restores the original signal efficiently [88]. An OR gate operates in parallel and produces an output if either Input A or Input B is active [87]. In order to ensure that every chemical cue can individually trigger production, this can be physically constructed by building a genetic circuit with two copies of a desired gene, each controlled by a distinct inducible promoter. Use of universal logic gates like NAND and NOR gates to build intricate, multi-layered decision-making systems [90]. By combining these universal gates, we can construct any mathematical function in computer engineering. For example, a biological NOR gate only generates an output when both inputs are totally missing [92]. By stacking these universal modules together using characterized, non-interacting components from standard sources, layered genetic networks can be created that can perform difficult mathematical functions [90]. For instance, a cell can be engineered to function as a cancer sensor, making an internal diagnostic determination by determining whether a tumour suppressor is inactive AND an oncogenic signal is active before producing a therapeutic protein by itself [30].

5.4. Combinatorial and multi-input circuits

Similar to biological regulatory systems where many transcription factors regulate a single gene, combinatorial and multi-input circuits combine several biological stimuli to generate a specific gene-expression output. Studies on synthetic promoters have demonstrated that various regulatory outputs can be produced by manipulating the quantity and configuration of transcription-factor binding sites [93]. Research showed that combinations of regulatory motifs might quantitatively dictate promoter activity, while combinatorial promoters could yield a wide variety of expression levels. Subsequently, reusable synthetic logic gates were created, such as NAND, NOR, and NOT gates, showing that programmable genetic circuits may incorporate many regulatory inputs. These results demonstrated combinatorial regulation as an essential strategy for creating cells that react only to particular signal combinations.

6. Machine learning and AI for miRNA network analysis and synthetic circuit engineering

The field of biology has already benefited greatly from machine learning (ML) techniques, particularly with the emergence of AlphaFold, which allows for extremely precise prediction of protein structures. These machine learning techniques are currently being used for predicting molecular interactions that occur between ions, proteins, nucleic acids, and small molecules. In addition to these prediction models, a new class of models is showing potential for generating de novo proteins with desired properties [94,95]. ML can be applied to the design of standardized biomolecules and genetic components in biological circuit design. Additionally, ML techniques could improve engineering by making it possible to predict biological circuit behaviour in situations when biophysical models fail [96]. Numerous studies have shown how ML may be used to generate different genetic sequences in relation to sequence-to-function prediction. Promoters, cis-regulatory elements, ribosome binding sites, untranslated regions, and protein design techniques are among the many examples. These computational techniques have proven to have a high predictive value when compared to other techniques, demonstrating the capacity of machine learning techniques to capture intricate biological interactions that can be challenging to model using alternative techniques. Additionally, ML has been used to build RNAs and riboswitches, allowing for more effective circuit element engineering [97,98]. BioAutoMATED is an example of an ML tool developed for automated modelling and standard design in order to promote accessibility and wider use of ML methods for designing genetic sequences [99]. In the context of sequence-to-function prediction, numerous studies have demonstrated the design of various genetic sequences using ML. Examples include methods to design promoters, cis-regulatory elements, ribosome binding sites, untranslated regions, and proteins. These computational methods have demonstrated high predictive power compared to other methods, which highlights the ability of ML methods to capture complex biological relationships that can be difficult to model with other approaches. ML has also been applied to the design of riboswitches and RNAs, enabling more efficient circuit component engineering [96]. More recently, next-generation genomic foundation models have extended this paradigm towards broader representation of genomes across diverse organisms, suggesting that ML-based design may eventually operate across scales ranging from individual regulatory elements to complete genetic programmes [100].

The relevance of these developments becomes particularly apparent in therapeutic genetic circuits, where circuit performance depends not only on the intrinsic activity of individual components but also on their interactions with the host-cell environment. ML can complement mechanistic models by learning these complex networks of cellular processes directly from experimental observations [96,101]. Hybrid approaches combining mechanistic modelling with ML are consequently attractive because they retain biologically interpretable constraints while allowing the model to capture behaviours that are difficult to represent using first-principles equations alone [101,102]. An important advantage of ML is its potential to automate circuit architecture and component selection. In principle, an ML-guided design framework can evaluate large numbers of possible promoters, regulatory sequences, repressors, activators, RNA elements, and circuit topologies before experimental testing. In synthetic biology, automated design tools can similarly translate desired input–output behaviour into candidate genetic architectures. For example, computational approaches have been developed to design genetic circuits and identify architectures capable of performing oscillation, switching, counting, and other complex functions [103]. However, there are several limitations before applying ML to therapeutic genetic circuit design. Biological datasets are often substantially smaller and more heterogeneous than datasets used in conventional AI applications. Diverse data are generated using different cell types, strains, experimental protocols, instruments, growth conditions, and normalization procedures, making apparently similar datasets difficult to combine [104,105]. Moreover, many published datasets preferentially contain successful constructs, whereas failed designs and negative experimental results are less frequently reported. This creates selection bias and limits the ability of models to learn the boundaries between functional and non-functional biological designs [106]. Another complication is the stochastic nature of biological systems. Unlike conventional digital circuits, biological logic gates do not operate under perfectly deterministic conditions [107]. Transcription and translation occur through probabilistic molecular events, while fluctuations in transcript abundance, protein concentration, plasmid copy number, and cellular state can generate substantial cell-to-cell variation [108]. Any kind of burden imposed by the synthetic circuit can alter host physiology, which in turn changes circuit performance [109]. Consequently, a circuit predicted to behave as an ideal AND, OR, NOT, or NOR gate in silico may display intermediate or heterogeneous states experimentally [107]. Molecular noise can therefore affect both the accuracy of therapeutic decision-making and the reproducibility of the downstream therapeutic response.

For therapeutic applications, another critical challenge is the distinction between predictive performance and biological validity. A high-performing ML model does not necessarily imply that its generated sequences will function as predicted in living cells. Model predictions can be affected by distribution shift when a sequence is introduced into a cellular context that differs from the training data [110]. Furthermore, sequence-level predictions may not capture chromatin accessibility, epigenetic regulation, protein abundance, subcellular localization, immune responses, metabolic burden, or interactions with endogenous regulatory networks. Consequently, computationally generated circuit designs require systematic experimental validation before they can be considered therapeutically meaningful. This creates an important opportunity to combine ML with automated experimentation and iterative DBTL workflows [111]. Rather than using ML as a one-time predictor, an adaptive system can use experimental results to continuously update its model and select the next most informative experiments. Bayesian optimization, active learning, reinforcement learning, and related approaches can prioritize experiments that either maximize expected circuit performance or reduce uncertainty in poorly characterized regions of the design space [112]. Automated platforms have already demonstrated the feasibility of coupling predictive models with robotic experimentation to explore biological design spaces more efficiently than conventional random screening. This iterative framework is particularly valuable for emerging therapeutic paradigms such as living therapeutics, programmable cell therapies, miRNA-responsive circuits, cell-state classifiers, and synthetic gene networks [113]. A unified integration of data interfaces that feed into a single hybrid modelling framework allows these divergent approaches to converge. Instead of functioning independently, the neural network and mathematical equations share information in both directions, resulting in a limited optimization environment. Because of this structural synergy, the hybrid framework could adhere to basic biological principles, including mass-action kinetics, while utilizing machine learning’s great predictive power to resolve the intricate intracellular conditions that biophysical equations are not able to define. Multiple transfer curves connecting input-output dynamics effectively demonstrate the actual usefulness of this integrated model Figure 6(A). The transfer curve that results from simulating circuit behaviour solely with the mathematical model shows a soft, flattened trajectory that greatly and incorrectly predicts the circuit’s operational limit and range of dynamics. On the other hand, the hybrid model accurately reproduces the real non-linear switching dynamics shown in the empirical data, producing a strongly sigmoidal transfer curve Figure 6(B,C). This alignment demonstrates how the prediction accuracy needed for the automated, in silico design of functional biological networks is achieved by combining data-driven machine learning with mechanistic limitations. Thus, machine learning enables the production of intelligent smart sensors like the cancer classifier by bridging the gap between digital biocomputing and complicated, multiplexed biological inputs.

Figure 6.

Machine learning-enhanced mechanistic modeling workflow. (A) schematic of the hybrid framework where host-circuit interaction data divided into features captured by classical mathematical models (red arrows) and those captured by machine learning (green arrows) are integrated to feed a unified hybrid model. (B) predicted transfer functions illustrating the dynamic shift between an isolated mathematical model (magenta) and the corrected, machine learning-enhanced hybrid model (dark blue). (C) empirical validation data plotting input versus output with standard deviation error bars, demonstrating the hybrid model’s superior accuracy in matching observed biological behavior.

Thus, ML is a computational layer connecting biological knowledge with high-throughput experimentation. The most promising future paradigm is likely to involve hybrid, uncertainty-aware models integrated into closed-loop DBTL platforms, where computational predictions are continuously challenged and refined by experimental measurements. Such systems could enable the transition from manually engineered genetic circuits to self-improving therapeutic design platforms capable of exploring large sequence and circuit spaces while explicitly accounting for biological noise, uncertainty, and context dependence. Nevertheless, clinical translation will require rigorous validation of model generalizability, reproducibility across cell types and manufacturing conditions, genetic stability, off-target activity, immunogenicity, and long-term safety. Addressing these limitations will be essential for converting the rapidly expanding predictive and generative capabilities of ML into reliable therapeutic genetic circuits and other programmable biological medicines.

7. miRNA-Based therapeutics and programmable therapeutic circuits

7.1. miRNA dysregulation in pathological States

Synthetic gene circuits have moved from theoretical biology into extremely successful clinical applications for both disease and health, especially those that make use of the post-transcriptional silencing potential of miRNAs (miRNAs). This programmable logic is transforming the treatment of viral or metabolic diseases, cancer, and regenerative therapies in human medicine. The primary application of synthetic miRNA-driven circuits is in the treatment and diagnosis of cancer, where the circuits function as sophisticated molecular classifiers. A synthetic multi-input logic circuit can be constructed to assess the very particular dysregulated miRNA expression profiles found in various malignant tumours within a living cell. The multi-input miRNA classifier circuit designed to specifically target HeLa cervical cancer cells is a classic example [114]. This system sequentially samples five distinct endogenous miRNAs and functions as a sophisticated biological AND-GLN (gate-like network). It is designed to detect the low level of expression of certain tumour-suppressive miRNAs combined with the high expression of particular oncogenic miRNAs. The most prominent success of synthetic miRNA-mediated circuits is in cancer therapeutics and diagnostics, where circuits act as intelligent molecular classifiers. Because different malignant tumours possess highly specific dysregulated miRNA expression profiles, a synthetic multi-input logic circuit can be designed to evaluate these signatures inside a living cell. A landmark example is the multi-input miRNA classifier circuit developed to selectively target HeLa cervical cancer cells [115]. This circuit operates as a complex biological AND-GLN (gate-like network) that samples five specific endogenous miRNAs simultaneously. It is programmed to identify the high expression of specific oncogenic miRNAs paired with the low expression of distinct tumour-suppressive miRNAs. The system only produces a positive classification signal output when the precise intracellular multi-miRNA profile of the cancer cell is fulfilled. This results in the autonomous cellular expression of a highly potent pro-apoptotic protein, such as active Caspase-3 or Bax, which destroys the cancerous cell while completely sparing healthy cells.

7.2. Innovative RNA-Based therapeutics and precision interventions

The miRNA mimics and antagomiRs/anti-miRs both show targeted modulation of endogenous miRNA activity (Table 1). MRX34 is a well-established example of a miRNA mimic, which is a liposomal formulation of a synthetic miR-34a mimic developed to regain the tumour-suppressive function of miR-34a, which is found frequently downregulated in several cancers, in a first-in-human phase I study, MRX34 demonstrated the feasibility of restoring endogenous miRNA activity therapeutically by producing dose-dependent modulation of miR-34a target genes [118].

Table 1.

Representative miRNA therapeutics, target indications, and clinical status.

Therapeutic Modality	Drug / Target Candidate	Disease Indication	Delivery Platform	Clinical Phase / Development Status	Key Reference(s)
miRNA Mimic	Remlarsen (MRG-201 / miR-29 mimic)	Keloids, fibrotic disorders	Intradermal/local delivery	Clinical development; Phase II completed	[116]
Anti-miR / AntagomiR	Miravirsen (SPC3649 / anti-miR-122)	Chronic hepatitis C virus (HCV) infection	LNA-modified antisense oligonucleotide	Phase II completed	[117]
miRNA Mimic	MRX34 (miR-34a mimic)	Advanced solid tumors, including HCC, melanoma, NSCLC	Liposomal nanoparticle	Phase I; terminated because of immune-related toxicity	[118]
Anti-miR / AntagomiR	Cobomarsen (MRG-106 / anti-miR-155)	Cutaneous T-cell lymphoma / mycosis fungoides	LNA-modified antisense oligonucleotide	Phase I/II clinical development; subsequently discontinued	[119]
miRNA Mimic	TargomiRs / MesomiR-1 (miR-16 mimic)	Malignant pleural mesothelioma; NSCLC	EGFR-targeted bacterial minicells (EnGeneIC EDVs)	Phase I clinical trial	[120]
Anti-miR / AntagomiR	Lademirsen (RG-012 / anti-miR-21)	Alport syndrome	Chemically modified antisense oligonucleotide; subcutaneous administration	Phase II completed; terminated for futility	[121]
Anti-miR / AntagomiR	RG-101 (anti-miR-122)	Chronic HCV infection	GalNAc-conjugated oligonucleotide	Phase Ib clinical trial	[122]
miRNA Mimic	miR-26a	Hepatocellular carcinoma	Adeno-associated viral (AAV) vector	Preclinical in vivo validation	[123]
Anti-miR / AntagomiR	Anti-miR-10b	Metastatic breast cancer	Antisense/anti-miR oligonucleotide	Preclinical in vivo validation	[124]
Anti-miR / AntagomiR	RGLS4326 (anti-miR-17)	Autosomal dominant polycystic kidney disease (ADPKD)	Chemically modified short antisense oligonucleotide	Preclinical and clinical development	[125]
Anti-miR / AntagomiR	CDR132L (anti-miR-132)	Heart failure / cardiac remodeling	LNA-modified antisense oligonucleotide; intravenous	Phase Ib/II clinical evaluation	[126]
Synthetic Genetic Circuit	Multi-input miRNA/RNAi cell classifier	Cancer-cell identification and selective killing	Synthetic RNAi/miRNA-responsive circuit	Preclinical; experimentally validated	[127]
Synthetic Genetic Circuit	RNA-based AND-gateimmunomodulatory circuit	Cancer immunotherapy	Lentiviral delivery of synthetic RNA circuit	Preclinical in vivo validation	[128]

AntagomiR-122, which was developed to block the liver-specific miR-122, and miravirsen (SPC3649), an LNA-modified anti-miR-122 that was studied for the treatment of hepatitis C virus infection, are two examples of the complementary loss-of-function technique. High affinity for miR-122 and enhanced nuclease resistance are provided by miravirsen’s LNA nucleotides within a phosphorothioate-containing backbone [129]. Therefore, a key component of these oligonucleotides’ action is chemical alteration. Anti-miR-122 has been widely used to demonstrate LNA modification; in hepatocyte-derived cells, an LNA/DNA mixmer with a phosphorothioate backbone caused dose-dependent reduction of miR-122 and subsequently proved effective miR-122 suppression in vivo [130]. 2’-O-methyl (2’-OMe) modification is another widely used strategy in which chemically altered 2’-OMe oligonucleotides are utilized to suppress carcinogenic miR-21, with further terminal and backbone modifications enhancing resistance to nucleases and inhibitory efficacy [131]. To enhance nuclease resistance, pharmacokinetic characteristics, and tissue exposure, phosphorothioate (PS) backbones are often combined with LNA or 2’-OMe chemistry. For instance, the LNA-antimiR-122 used in preclinical studies included a fully phosphorothioate backbone [130]. Together, these illustrations show how sequence complementarity gives miRNA selectivity, while chemical modifications like LNA, 2’-OMe, and PS enhance the stability, affinity, and in vivo efficacy of therapeutic oligonucleotides.

7.3. Synthetic gene circuits as cell-based living therapeutics

Synthetic circuits are used in stem cell engineering and regenerative medicine as precise safety switches in addition to directly destroying cells. Although induced pluripotent stem cells (iPSCs) have enormous potential for tissue regeneration, if cells that have not been differentiated contaminate the transplant, there is a serious clinical risk of teratoma development. Artificial circuits have been created that detect pluripotency-associated miRNAs, like the miR-302/367 cluster, to get around this problem [132]. If a stem cell fails to differentiate and maintains high levels of this pluripotency marker, the circuit activates an inducible suicide triggering mechanism (such as Herpes Simplex Virus Thymidine Kinase, or HSV-TK). This ensures the safety of the engineered tissue graft by removing the dangerous, undifferentiated stem cells from the entire population. Synthetic circuits offer dynamic, real-time approaches that are better than conventional medications in the treatment of infectious diseases. For instance, the Hepatitis C virus (HCV) actively uses the host molecule miR-122, which is particular to the liver, to aid in its own genome replication throughout long-term viral infections [133]. By constructing competitive RNAi-based feedback networks and antagomiR or sponge circuits which actively capture abundantly expressed viral-aid miRNAs, synthetic biologists have successfully stopped the viral lifecycle in real time [134]. Similar to this, in metabolic diseases like diabetes, ligand-responsive ribozymes are linked to synthetic negative feedback loops to monitor changing systemic parameters, like real-time blood glucose or inflammation markers, enabling implantable biodevices to independently produce and secrete computed, therapeutic doses of insulin or anti-inflammatory proteins [135].

8. Challenges and future perspective

8.1. Translational barriers: delivery, safety, immunogenicity, off-target effects, and regulatory challenges

Despite the enormous potential of synthetic biology, the translation from mathematical models towards functional intracellular designs continues to be constrained by several fundamental reasons. Context dependency is a major obstacle, as a genetic circuit that functions consistently in one cell line fails or behaves differently when transfected into a different cell line [136]. This phenotypic shift occurs because synthetic circuits compete directly with the genome of the host for limited cellular machinery, such as endogenous RNA Polymerase II, splicing factors, and ribosomal subunits. When a circuit is placed under an excessive metabolic burden on these shared resources. This burden impairs cell physiology, changes baseline transcription, or causes severe cellular toxicity. Moreover, biological parts often lack perfect orthogonality. Off-target interactions and molecular crossovers can occur in even well-characterized transcription factors or synthesized miRNAs (miRNAs), leading to leaky basal expression in which a logic gate never fully achieves an OFF state. This imprecision can lead to catastrophic failures in therapeutic cell classification methods, like the unintentional activation of pro-apoptotic genes in healthy tissue as a result of a minor modification in the circuit’s response threshold. There are substantial delivery and stability challenges to translate synthetic circuits into in vivo therapeutic settings. It is still challenging to deliver large, multi-cassette plasmid circuits into certain target tissues safely and effectively. Although viral vectors (such as lentiviruses or adeno-associated viruses) have a high transfection efficiency, there are ongoing clinical hazards related to immunogenicity, payload size restrictions, and possible insertional mutagenesis. On the other hand, non-viral administration methods, such as direct naked injection or lipid nanoparticles (LNPs), frequently experience rapid systemic elimination by the kidneys and are vulnerable to destruction by circulating serum nucleases [137,138]. One major obstacle is still achieving sustained expression without causing a long-term immunological reaction. Additionally, since a lot of artificial circuits depend on outside inducers like doxycycline to adjust transactivator activity, guaranteeing accurate induction through these adds another level of complexity to the system.

8.2. Future horizons in AI-Driven circuit design

In order to overcome these limitations, deep learning, sophisticated automation, and adaptive structural designs are essential for the future of synthetic biology. The paradigm is changing from human trial-and-error to predictive engineering with the use of Deep Learning (DL) architectures like convolutional neural networks and multi-layer perceptrons. Artificial intelligence (AI) systems may anticipate part orthogonality, optimize promoter strength, and create synthetic genetic parts with minimum cross-talk and reduced metabolic burden before physical DNA synthesis by training models on large sequence libraries [139]. Next-generation genetic circuits will provide the spatial and temporal precision needed to achieve truly personalized medicine by layering multi-input logic modules with resilient, noise-buffering network motifs.

8.3. Integrated paradigm from endogenous RNome to therapeutic translation

The integration of miRNA (miRNA) biology, computational modelling, and synthetic biology acts as a bridge connecting fundamental molecular discoveries with clinical precision medicine (Figure 7). An endogenous regulatory core controls complex interactions between miRNAs, transcription factors (TFs), and messenger RNAs (mRNAs) to buffer noise, preserve phenotypic identity, and maintain biological homeostasis. These interactions result in recurrent auto-regulatory feedback loops and co-regulatory feed-forward networks. Although network inference models and deep learning architectures methodically map interactions and optimize sequence design, computational analysis typically employs thermodynamic stability, seed sequence complementary pairing (nucleotides 2–8), and evolutionary sequence conservation to predict target sites in order to decipher these complex topologies [24]. To engineer modular genetic circuits consisting of miRNA-responsive input sensors (such as engineered miRNA Response Elements) and Boolean logic processing units (AND, NOT, OR gates), these computational design rules are utilised along with conditional output drivers resulting in the expression of cell-state-specific therapeutics or biomarkers [140]. Ultimately, this pipeline deploys static molecular agents including miRNA mimics to restore lost tumour suppression and anti-miRs or antagomiRs to sequester pathologically overexpressed oncomiRs as well as dynamic, programmable synthetic circuits that drive therapeutic translation, all of which require advanced delivery systems, rigorous safety and off-target toxicity profiling, and systematic evaluation across clinical trial phases.

Figure 7.

Integrated schematic pipeline linking endogenous miRNA regulatory networks to therapeutic translation. the workflow progresses across four interconnected tiers: endogenous biology: core regulatory motifs including auto-regulatory feedback and co-regulatory feed-forward loops formed by miRnas, TFs, and mRNAs. Computational analysis: in silico target prediction based on seed sequence conservation, network inference models, and deep learning algorithms for design optimization. Synthetic biology & circuit design: modular genetic circuits featuring miRNA-responsive input sensors, Boolean logic gates (AND, NOT, OR), and programmable conditional output drivers. Therapeutic translation: development of miRNA mimics, antagomiRs, and cell-classifier circuits coupled with advanced delivery platforms, safety/efficacy evaluations, and clinical trial progression.

9. Conclusion

The fundamental designs for current computational genetic structures can be discovered by the systematic mapping of miRNA-mediated regulatory networks, which offers a generative paradigm in post-transcriptional control. The transition from investigating canonical miRNA biogenesis and the severe phenotypic effects to understanding the topological structure of transcription factor-miRNA mixed networks demonstrates the multilayered complexity necessary to sustain cellular homeostasis. Synthetic biologists have effectively created physical digital logic gates that can carry out multi-input biocomputing programmes that operate within biological systems by treating these endogenous feedforward, feedback, and double-negative loops as natural information-processing units. However systemic issues with context dependency, promoter leakiness, and in vivo delivery vectors continue to be significant bottlenecks. Furthermore, the application of in silico machine learning architectures has moved the field from empirical trial-and-error to predictive, deterministic circuit engineering.

miRNAs are far more than just simple genetic haemostats or passive diagnostic indicators, instead they are the perfect molecular foundation for self-regulating biological software. Computational machine learning combined with synthetic gene circuit construction transforms a therapeutic approach by taking advantage of the predicted sequence complementarity and titrative kinetics present in RNA interference systems. This dual framework transforms medicine beyond traditional, reactive pharmacology and towards proactive, real-time cellular computing that can categorize complex disease conditions and filter the dynamic noise. The emergence of this field clearly points to a future dominated by closed-loop, intelligent biodevices that seamlessly interface with human physiology to perform regulatory homeostasis, even in the presence of the dense metabolic networks of host cell lines.

Funding Statement

The work was supported by the Department of Biotechnology, Ministry of Science and Technology, India [Intramural].

Disclosure statement

The authors declare that no financial support was received for the research and/or publication of this article. The authors report no other conflicts of interest.

Data availability statement

During the course of this study, no new datasets were generated or analysed. This article is based exclusively on previously published literature, and all sources are cited in the reference list.